File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Network meta-analysis of cardiovascular outcomes in randomised controlled trials of new antidiabetic drugs.

TitleNetwork meta-analysis of cardiovascular outcomes in randomised controlled trials of new antidiabetic drugs.
Authors
Issue Date2017
PublisherMedcom Limited. The Journal's web site is located at http://www.hkcchk.com/journals.php#3
Citation
The 25th Annual Scientific Congress of the Hong Kong College of Cardiology, Hong Kong, 16-18 June 2017. In The Journal of the Hong Kong College of Cardiology, 2017, v. 25 n. 1, p. 18 How to Cite?
AbstractPurpose: Few randomised controlled trials directly compared the effect of new antidiabetic drugs on cardiovascular outcomes in patients with type 2 diabetes (T2D). We performed a network meta-analysis to assess the cardiovascular effects of these drugs. Methods: We searched for randomised controlled trials that reported rates of major adverse cardiovascular events (MACE) and deaths in T2D patients with established cardiovascular risks, involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Data were analysed using frequentist approach and Bayesian framework in R. Results: Seven randomised controlled trials with altogether 62268 T2D patients were included for analysis. Compared to placebo, GLP-1 RAs and the SGLT-2 inhibitor reduced MACE (OR 0.89, 95%CI 0.82-0.97 and OR 0.85, 95%CI 0.73-0.99, respectively) and all-cause mortality (OR 0.89, 95%CI 0.80-0.99 and OR 0.67, 95%CI 0.55-0.81, respectively). The SGLT-2 inhibitor was more beneficial than GLP-1 RAs in reducing all-cause mortality (OR 0.76, 95%CI 0.61-0.94). DPP-4 inhibitors increased all-cause mortality when compared to GLP-1 RAs (OR 1.16, 95%CI 1.01-1.33) and the SGLT-2 inhibitor (OR 1.53, 95%CI 1.24-1.89). Conclusions: GLP-1 RAs and the SGLT-2 inhibitor reduced the risk of MACE and all-cause mortality. DPP-4 inhibitors were inferior to these two drug classes in reducing cardiovascular events. The SGLT-2 inhibitor was the best in preventing deaths among the three antidiabetic drugs classes.
DescriptionFree Paper Session
Persistent Identifierhttp://hdl.handle.net/10722/247878
ISSN
2015 SCImago Journal Rankings: 0.102

 

DC FieldValueLanguage
dc.contributor.authorFei, Y-
dc.contributor.authorTsoi, MF-
dc.contributor.authorKumana, CR-
dc.contributor.authorCheung, TT-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2017-10-18T08:34:06Z-
dc.date.available2017-10-18T08:34:06Z-
dc.date.issued2017-
dc.identifier.citationThe 25th Annual Scientific Congress of the Hong Kong College of Cardiology, Hong Kong, 16-18 June 2017. In The Journal of the Hong Kong College of Cardiology, 2017, v. 25 n. 1, p. 18-
dc.identifier.issn1027-7811-
dc.identifier.urihttp://hdl.handle.net/10722/247878-
dc.descriptionFree Paper Session-
dc.description.abstractPurpose: Few randomised controlled trials directly compared the effect of new antidiabetic drugs on cardiovascular outcomes in patients with type 2 diabetes (T2D). We performed a network meta-analysis to assess the cardiovascular effects of these drugs. Methods: We searched for randomised controlled trials that reported rates of major adverse cardiovascular events (MACE) and deaths in T2D patients with established cardiovascular risks, involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Data were analysed using frequentist approach and Bayesian framework in R. Results: Seven randomised controlled trials with altogether 62268 T2D patients were included for analysis. Compared to placebo, GLP-1 RAs and the SGLT-2 inhibitor reduced MACE (OR 0.89, 95%CI 0.82-0.97 and OR 0.85, 95%CI 0.73-0.99, respectively) and all-cause mortality (OR 0.89, 95%CI 0.80-0.99 and OR 0.67, 95%CI 0.55-0.81, respectively). The SGLT-2 inhibitor was more beneficial than GLP-1 RAs in reducing all-cause mortality (OR 0.76, 95%CI 0.61-0.94). DPP-4 inhibitors increased all-cause mortality when compared to GLP-1 RAs (OR 1.16, 95%CI 1.01-1.33) and the SGLT-2 inhibitor (OR 1.53, 95%CI 1.24-1.89). Conclusions: GLP-1 RAs and the SGLT-2 inhibitor reduced the risk of MACE and all-cause mortality. DPP-4 inhibitors were inferior to these two drug classes in reducing cardiovascular events. The SGLT-2 inhibitor was the best in preventing deaths among the three antidiabetic drugs classes.-
dc.languageeng-
dc.publisherMedcom Limited. The Journal's web site is located at http://www.hkcchk.com/journals.php#3-
dc.relation.ispartofJournal of the Hong Kong College of Cardiology-
dc.titleNetwork meta-analysis of cardiovascular outcomes in randomised controlled trials of new antidiabetic drugs.-
dc.typeConference_Paper-
dc.identifier.emailKumana, CR: hrmekcr@hku.hk-
dc.identifier.emailCheung, TT: tcheungt@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, TT=rp01682-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.hkuros282092-
dc.identifier.volume25-
dc.identifier.issue1-
dc.identifier.spage18-
dc.identifier.epage18-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats